Ju L, Huang-fu Y, Zhang L
PLA 302nd Hospital, Beijing.
Zhonghua Yi Xue Za Zhi. 1996 Feb;76(2):124-7.
To observe the internalization process of asialoglycoprotein receptor mediated antiviral conjugate lactosaminated human albumin arabinoside adenine monophosphate (L-HSA-Ara-AMP) in human hepatoma cell line HepG-2, and provide the specificity and practicability of receptor targeting treatment of viral hepatitis.
Colloidal gold labelling technique combined with electronmicroscopic observation was employed. The study was carried out in three groups: experiment group (the internalization of antiviral conjugate in HepG-2 cell line), positive control group (lactosaminated human serum albumin), and negative control group and (human serum albumin).
L-HSA-Ara-AMP can be specially recognized and uptaken by the cells and enter the cells via coated pit. After internalization, the antiviral conjugate entered the lysosome ultimately.
The therapy of asialoglycoprotein receptor targeting treatment of viral hepatitis has a high specificity. The therapy is worth further study.
观察去唾液酸糖蛋白受体介导的抗病毒偶联物乳糖胺化人白蛋白单磷酸阿糖腺苷(L-HSA-Ara-AMP)在人肝癌细胞系HepG-2中的内化过程,为病毒性肝炎受体靶向治疗的特异性和实用性提供依据。
采用胶体金标记技术结合电子显微镜观察。实验分为三组:实验组(抗病毒偶联物在HepG-2细胞系中的内化)、阳性对照组(乳糖胺化人血清白蛋白)和阴性对照组(人血清白蛋白)。
L-HSA-Ara-AMP能被细胞特异性识别并摄取,通过有被小窝进入细胞。内化后,抗病毒偶联物最终进入溶酶体。
去唾液酸糖蛋白受体靶向治疗病毒性肝炎具有较高的特异性,值得进一步研究。